Germany legalizes Weed, this stock is up big as a result

Today’s big movers inside                                                                                                                                                                                                                                                                                                                                                                                                                 March 25, 2024 Germany legalizes Weed, this stock is up big as a result *contains sponsored content Hey 360! This is going to be a very important week for the market. Make sure you are hitting the week prepared with all of the top ideas you want to trade. Get started this morning by joining us for LIVE TRADING action all day long in the [Market Master’s trading room](. See what traders are saying about today’s focus stock and dozens of other breaking stocks that are moving during the day. Be the best prepared trader on the Street! FOCUS LIST FLGC - 2nd day play up over 30% in the pre-market after press release Friday regarding Germany's cannabis legalization SLRX - Up over 25% in pre after reporting better than expected earnings and implementing significant expense-reductions measures ESPR - Up over 20% in pre after receiving FDA approval Friday for NEXLETOL® and NEXLIZET® to Prevent Heart Attack SPOTLIGHT *sponsored content Today’s hot stock is a volatile AI stock with a history of huge moves that is looking to transform a very lucrative industry. Here is a sneak peek at the stock chart right now. As you can see, it is sitting on the lower end of a pullback and has already started to trade back about the hourly level. ✅ We even have double “GO” signals firing off for confirmation… It is trading a tad under $1 right now, which always gets us excited. First of all, from that level, it doesn’t take a big move to be a big percentage increase (or decrease if it goes against you). While you’ll be hard-pressed to find many stocks that will make even a 1% move today, just think what a paltry $.10 move can do on a stock like this? For perspective, it would be a full 30% move higher just to take it back to the $1.20 resistance level it hit last week, or over a DOUBLE if it makes it back to the $2 it saw a few weeks ago. As you can see, the potential with this one is enormous right now. You can be the first one to [see our quick report by clicking over to this page]( today @ 9:30 am EST. You are really going to love this business, too but make sure to do all your homework on it and [head on over to this page at 9:30AM](! THE HOTLIST FLGC - 2nd day play up over 30% in the pre-market after press release Friday regarding Germany's cannabis legalization Flora Growth Corp. (FLGC) together with its subsidiaries, engages in the growth, cultivation, and development of medicinal cannabis and medicinal cannabis derivative products to pharmacies, medical clinics, and cosmetic companies worldwide. On Friday, the [company issued a press release]( commending Germany's upper house lawmakers for passing the recreational cannabis legalization bill, after it was approved by the lower house last month. The law is now expected to come into effect on April 1, 2024. The law cleared its final hurdle, making German laws on cannabis use among the most progressive in the world. Flora's wholly-owned subsidiaries have been active in Germany since 2017, obtained the first medical cannabis license in Germany and are responsible for selling the first gram of medical cannabis in the country. The stock traded up over 30% in the pre-market this morning after closing up over 30% on Friday after the press release The $2 area was resistance in the after-hours and pre-market and will be an important level to watch. Above it, the first target for bulls is the pre-market high at $2.36. Beyond that, $2.80, $3 and $3.40 come into play. Below $2, targets to the downside are at $1.80, $1.60 and $1.50. SLRX - Up over 25% in pre after reporting better than expected earnings and implementing significant expense-reductions measures Salarius Pharmaceuticals, Inc. (SLRX) is a clinical-stage biotechnology company that focuses on developing treatments for cancers with unmet medical need. In the after-hours on Friday[the company reported]( Q4 Net loss of $0.9 million, or $0.22 per share vs 2022 Q4 net loss of $6.4 million, or $2.83 per share, reflecting lower operating expenses resulting from the cost-savings plan implemented in the third quarter of 2023. Cash and cash equivalents were $5.9 million as of December 31, 2023, The company stated: “During the second half of 2023 and the first months of 2024, Salarius reduced operating expenses, allowing us to extend our cash runway to generate additional clinical data in the seclidemstat hematologic and Ewing sarcoma clinical trials. We believe these data, if positive, will further enhance our opportunities to maximize shareholder value,” The stock traded up over 25% in the pre-market after the news. $0.75 has acted as support in the pre-market and will be an important level to watch. Above it, targets to the upside are $0.86, and then the after-hours high at $0.9842. Beyond that $1.10, $1.24 and $1.50 come into play. Below $0.75, targets to the downside are $0.70 and then a gap fill at $0.62. Accelerator Starts TODAY! [4 Week Options Selling Training]( Your chance to learn all our TOP strategies in a small-group environment starts THIS Monday - daily 12pm EST (times may vary). All sessions recorded for on-demand learning – no excuses! Contact Davis for more info: 1-800-585-4488 / davis@ragingbull.com ESPR - Up over 18% in pre after receiving FDA approval Friday for NEXLETOL® and NEXLIZET® to Prevent Heart Attack Esperion Therapeutics, Inc. (ESPR) is a pharmaceutical company that develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). On Friday, the [company announced]( that the FDA had approved broad new labels for Esperion’s NEXLETOL® and NEXLIZET® to prevent heart attacks and cardiovascular procedures in both primary and secondary prevention patients, regardless of statin use. The new labels expand treatable population to ~70 million patients in the U.S. The stock traded up over 20% in pre-market after the news Friday. $2.70 has acted as a support area in the pre-market and will be an important level to watch. Above it, targets to the upside are $2.85 and then the after-hours high at $2.89. Beyond that $3, $3.30 and $4 come into play. Below $2.70, targets to the downside are, $2.50, $2.40 and then a gap fill at $2.29. Economic Calendar (EST) 👊 By the way, if you are NOT getting our mobile text alerts –  text “RAGE” to 1-(888) 404-5747 to get all of our latest HOT STOCK ideas delivered right to your phone (make sure you put the “1” at the front!). Don’t miss out!  Questions or concerns about our products? Email [Support@360wallstreet.io]( © Copyright 2022, RagingBull  DISCLAIMER To more fully understand any Ragingbull.com, LLC ("RagingBull") subscription, website, application or other service ("Services"), please review our full disclaimer located at [( *PAID ADVERTISEMENT. RagingBull has been paid twenty thousand dollars by a sponsoring company to produce and distribute this content. See the host page for full compensation terms. This investment involves substantial risk. Please see full disclosures on the host page, and detailed discussion of risks and atypical results. FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Any RagingBull Service offered is for educational and informational purposes only and should NOT be construed as a securities-related offer or solicitation, or be relied upon as personalized investment advice. RagingBull strongly recommends you consult a licensed or registered professional before making any investment decision. RESULTS PRESENTED NOT TYPICAL OR VERIFIED. RagingBull Services may contain information regarding the historical trading performance of RagingBull owners or employees, and/or testimonials of non-employees depicting profitability that are believed to be true based on the representations of the persons voluntarily providing the testimonial. However, subscribers' trading results have NOT been tracked or verified and past performance is not necessarily indicative of future results, and the results presented in this communication are NOT TYPICAL. Actual results will vary widely given a variety of factors such as experience, skill, risk mitigation practices, market dynamics and the amount of capital deployed. Investing in securities is speculative and carries a high degree of risk; you may lose some, all, or possibly more than your original investment. RAGINGBULL IS NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Neither RagingBull nor any of its owners or employees is registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. Employees, owners, and other service providers of https:// ragingbull. com or RagingBull.com LLC are paid in whole or in part by commission based on their sales of Services to subscribers. RagingBull.com, LLC shall be entitled to recover attorneys’ fees, costs and disbursements. In the event that any suit or action is instituted as a result of doing business with RagingBull. com, LLC and/or its affiliates or if any suit or action is necessary to enforce or interpret these Terms of Service, RagingBull. com, LLC shall be entitled to recover attorneys’ fees, costs and disbursements in addition to any other relief to which it may be entitled. WE MAY HOLD SECURITIES DISCUSSED. RagingBull has not been paid directly or indirectly by the issuer of any security mentioned in the Services except possibly by advertisers in this email. However, Ragingbull.com, LLC, its owners, and its employees may purchase, sell, or hold long or short positions in securities of the companies mentioned in this communication. [tw]( Update your email preferences or unsubscribe [here]( © 2024 360wallstreet 62 Calef Hwy. #233 Lee, NH 03861, United States of America